医学
肠道菌群
肠易激综合征
梅德林
人体微生物群
微生物群
疾病
系统回顾
人体研究
益生菌
炎症性肠病
结直肠癌
动物研究
粪便细菌疗法
重症监护医学
生物信息学
免疫学
癌症
抗生素
内科学
生物
艰难梭菌
微生物学
生物化学
细菌
遗传学
作者
Jakub Ruszkowski,Zofia Kachlik,Michał Walaszek,Dawid Storman,Karolina Podkowa,Paweł Garbarczuk,Paweł Jemioło,Weronika Łyzińska,Katarzyna Nowakowska,Konrad Grych,Alicja Maria Dębska-Ślizień
标识
DOI:10.1186/s12967-025-06645-6
摘要
BACKGROUND: Fecal microbiota transplantation (FMT) from humans with specific medical conditions to animal models can demonstrate causality by inducing or exacerbating pathophenotypes, linking the gut microbiota to health outcomes. METHODS: We conducted a scoping review searching MEDLINE, EMBASE, Scopus, and Web of Science through July 2024 to identify human noninfectious diseases studied using FMT in animal models, investigate FMT methodologies, and assess the feasibility of systematic reviews on the role of the microbiota in specific diseases. RESULTS: From 605 reports of 489 studies, we found that inflammatory bowel diseases, irritable bowel syndrome, obesity, colorectal cancer, and depression were the most commonly studied, with cancer research focusing on immunotherapy non-responsiveness. In a random sample of studies, gastrointestinal outcomes were most frequently reported, with remarkably high rates (> 80%) of successful induction of disease-specific alterations for intestinal barrier function, gastrointestinal inflammation, circulating immune parameters, and fecal metabolites. Most studies used C57BL/6 mice and oral gavage administration, with recipients being either germ-free or antibiotic-pretreated. We created tables linking conditions with publications to facilitate future systematic reviews. CONCLUSIONS: Although human-to-animal FMT studies cover diverse conditions, methodological heterogeneity and inconsistent reporting hinder comparability. Standardized protocols and guidelines are needed. For several conditions, sufficient literature exists to assess the role of the gut microbiota in human health through systematic reviews.
科研通智能强力驱动
Strongly Powered by AbleSci AI